FPRX Five Prime Therapeutics Inc.

3.92
+0.03  (+1%)
Previous Close 3.89
Open 3.81
Price To Book 0.7
Market Cap 144,183,029
Shares 36,781,385
Volume 319,733
Short Ratio
Av. Daily Volume 367,143
Stock charts supplied by TradingView

NewsSee all news

  1. Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting

    - Results Demonstrate FPT155 was Well Tolerated in all Patients through Seven Cohorts, Allowing for Continuation of Dose Escalation and Dose Finding - Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage

  2. Five Prime Therapeutics Reports Third Quarter 2019 Results

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced its results for the third

  3. Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2019 financial

  4. Five Prime Announces Restructuring

    Clinical Timelines Not Impacted and $20 Million of Annualized Savings Expected Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators

  5. Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress

    - Results Provide First Clinical Demonstration of B7-H4 as a Potential Therapeutic Target and Continue to Support FPA150's Greatest Potential in Combination Therapy - Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 futility analysis due mid-2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 1b ongoing.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Solid tumors
Phase 2 complete. Phase 3 development will not be pursued.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data at ESMO showed ORR 48%.
FP-1039
Mesothelioma cancer
Phase 1b initial data due at ESMO 2019 noted 2 PRs.
FPA150
Solid tumors
Phase 2 data due 2020.
Cabiralizumab (FPA008) and Opdivo (nivolumab)
Pancreatic cancer
Phase 1 data at SITC November 9, 2019 - well tolerated.
FPT155
Solid tumors

Latest News

  1. Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting

    - Results Demonstrate FPT155 was Well Tolerated in all Patients through Seven Cohorts, Allowing for Continuation of Dose Escalation and Dose Finding - Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage

  2. Five Prime Therapeutics Reports Third Quarter 2019 Results

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced its results for the third

  3. Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2019 financial

  4. Five Prime Announces Restructuring

    Clinical Timelines Not Impacted and $20 Million of Annualized Savings Expected Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators

  5. Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress

    - Results Provide First Clinical Demonstration of B7-H4 as a Potential Therapeutic Target and Continue to Support FPA150's Greatest Potential in Combination Therapy - Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a

  6. Five Prime Therapeutics Announces Management Transition

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today that its Board

  7. Five Prime Therapeutics to Present at Upcoming Healthcare Conference

    Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief